March SLAS Discovery explores pharmacological treatments for COVID-19 six months later

Oak Brook, Illinois – March issue of Discover SLAS Features cover article, “Treatment Options and Vaccines for COVID-19: The Condition 6 Months After the Outbreak” by Christian Ogogo (Federal University of Oye-Ekiti, Ekiti State, Nigeria), Dawid Maciorowski, Subba Rao Durvasula, Ph.D. Ravi Dorvasula, MD, and Adinarayana Konaminini, PhD. (Loyola University Medical Center, Maywood, Illinois, USA).

This cover article focuses on the treatment options and vaccines available against the new coronavirus, nearly six months after the outbreak; With the number of COVID-19-related deaths worldwide reaching 500,000 in six months (and ballooning to more than 2,000,000 at time of publication), the importance of options to mitigate the disease cannot be overemphasized. The article highlights treatment alternatives available for mild and serious active cases of COVID-19 infection and explores vaccine options that should help give immunity to vaccinated individuals. In addition to providing information about the options available to tackle COVID-19, this article summarizes the global efforts being made to end the epidemic. The authors concluded that a combination therapy should be tailored to both vaccines as well as small compounds. Other articles in this issue discuss the repurposed therapies used to treat COVID-19 cases, as well as the promising vaccines in various stages of clinical trials.

March issue of Discover SLAS It includes nine original research articles plus a cover article.

Original research articles include:

  • Defining a CETSA MS profile for a comparative evaluation of FDA-approved antiviral drugs reused for treating COVID-19 identifies Trip13 as Remdesivir off target
  • A scalable approach reveals functional responses to iPSC Cardiomyocyte 3D spheroids.
  • Assessment of arrhythmia potential in human-induced electrolyte-induced ventricular stem cells derived from ventricular stem cells using a multi-electrode array
  • Major improvements in durability and efficiency while screening new enzyme responders with the 3-point kinetics test
  • Optimization of the colorimetric assay to determine lactate dehydrogenase B activity using an experimental design
  • AlphaScreen identifies MSUT2 inhibitors for therapeutic discovery targeting angiopathy
  • Leveraging automation in developing a high-throughput platform for gene expression
  • Quantitative automated assays in live cells to detect inhibitors of Hemichannel function
  • ‘Target group’ screen for identifying K2P
  • Development of a cell-based assay to identify KCa3.1 inhibitors using intestinal epithelial cell lines
  • Characterization of the Urate vector, GLUT9, and its potent inhibitors by Patch-Clamp technology

Other articles include:

  • Treatment options and vaccines for COVID-19: the condition six months into the outbreak
  • Saporin, a Polynucleotide-Adenosine Nucleosidase, may be an effective treatment agent for SARS-CoV-2 infections.
  • Comparison analysis: a bioinformatics approach to accelerate drug reuse against COVID-19 and other emerging epidemics
  • Comprehensive parallel examination of all types of optics to study the dependent operation of the use of voltage ion channels in miniature format


Arrive in March Discover SLAS The version is available at https: //Magazines.sagepub.Com /Methods /jbxb /26 /3.

For more information on SLAS and its journals, visit http: // www.slas.Deer /Magazines. Access the “behind the scenes” look at the latest release with Discover SLAS Author Insights Podcast. Visit the website https: //www.buzzsprout.Com /1099559.

SLAS (Laboratory Automation and Inspection Association) is an international professional association for academic, industrial and governmental researchers in the life sciences and developers and providers of laboratory automation technology. The mission of SLAS is to bring together researchers in academia, industry, and government to advance the discovery of life sciences and technology through education, knowledge sharing, and global community building.

Discovering SLAS: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, Massachusetts (USA).

SLAS Technology: Translating Life Science Innovations, 2019 Impact Factor 2.174.2. Editor-in-chief, Edward Kai Hwa Chau, Ph.D., National University of Singapore (Singapore).

Media contact
Jill burned you
[email protected]https: //Magazines.sagepub.Com /Methods /jbxb /26 /3

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button